Aneurysm Treatment using the HeliFX™ Aortic Securement System Global Registry (ANCHOR Registry)
ID Number 12-1925Principal Investigator(s)
Sharif H Ellozy
Department(s) or Division(s)
"Aneurysm Treatment using the HeliFX Aoritc Securment System Global Registry," also known as ANCHOR, is a registry study designed to collect information surrounding the use and long-term effects of the Aptus HeliFX™ Aortic Securement System. This FDA-approved device was developed in response to common complications, including but not limited to Type 1a endoleaks and ruptures, caused by poor attachment of an endograft to the aortic wall. An endograft is used during endovascular aneurysm repairs, a minimally invasive treatment option for abdominal aortic aneurysms (AAA). AAA occurs when the large blood vessel (aorta) that supplies blood to the abdomen, pelvis, and legs becomes abnormally large due to weakness of the artery. An endograft is able to prevent rupture by covering and protecting the aortic wall. Once an endograft has been placed, long-term observation is required to guarantee that the graft remains in the correct position. The use of the Aptus device is designed to secure the endograft to the aortic wall and prevent this possible movement.
This Registry will include up to 2,000 patients from approximately 70 centers within and outside the United States. Patients who participate in this registry will be followed for 5 years after the surgery during which the Aptus device was implanted.
Recruiting Patients: Yes